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Letter to Editor 
 
 Dear Editor, 
 
Extensive discussions about the applicability of rapid diagnostics 
kits/tests for corona virus disease 2019 (COVID-19) detection has taken 
place in Nepal. A critical, and authentic information about the kit is 
necessary in order to fight the COVID-19 infection. Online news portal 
eKantipur 12 April, 2020 reported that "Wondfo" kit made by the 
Guangzhou Wondfo Biotechnology company was bought by Nepal 
Government.1 The National Medical Product Association of China, until 
16 March 2020, has given emergency approval to 19 SARS-CoV-2 (Severe 
Acute Respiratory Syndrome Corona virus-2)  detection kits among which 
8 are based on immunological assay.2 The Wondfo kit is a lateral flow-
based assay utilizing colloidal gold for visualization as reported in Chinese 
science news portal ScienceNet.cn on 24 February 2020.3 This science 
new portal, a part of China Science Daily Media Group, is claimed to be a 
Chinese language virtual community of Chinese scientists, co-sponsored 
by Chinese Academy of Sciences, Chinese Academy of Engineering, 
National Natural Science Foundation of China and China Association for 
Science and Technology.4 It reported that National Medical Product 
Association gave emergency permission for the use of the kit to diagnose 
COVID-19 and has mentioned that it was the first kit of its kind to detect 
COVID-19 infection and to be granted approval for use. The official China 
medical equipment government validation number of the kit is 
20203400176. The news said that the kit doesn't differentiate between 
IgG or IgM antibodies but detects both, increasing the chance of 
detection of serological conversion of COVID-19 patients. The news 
reported that Dr. Zhong Nan Shan, an academician at the Chinese 
Academy of Engineering,5 said the kit was able to detect infection on the 
7th day of infection and 3rd day of onset of symptoms. Scientifically, this 
means the kit can't detect infection before 7th day of being infected or 
before 3rd day of start of symptoms. The news clearly mentions the kit 
would help “supplement or synergize” i.e. “buchong or xietong” in 
Chinese (Youdao translation, https://en.wikipedia.org/wiki/Youdao), the 
results of PCR (polymerase chain reaction) tests. 
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The news section in the official website of 
Wanfu biotech, on 6 March 2020, says that 
the "Wondfo SARS-CoV-2 Antibody Test 
(Lateral Flow Method)" had got EU CE label.6 
This is European Union's "European 
Confirmation" for the kit meeting the high 
safety, health, and environmental protection 
requirements for use in the European Union 
countries. China Daily, an English language 
newspaper in China, confirms it.7 
 
Search for "Wondfo coronavirus" not "wanfu 
coronavirus" in the Google Scholar resulted in 
a scientific article uploaded in MedRxiv 
(pronounced med-archive) website. The 
MedRxiv is a preprint server which, after 
screening for non-scientific content and 
plagiarism,  assists authors to posting their 
articles which are not yet peer-reviewed.8 The 
study from Nanjing Medical University, China, 
used the kit to check the infectivity of 13 
patients and 9 showed positive tests. But the 
tests were carried 15 to 40 days after the 
onset of symptoms.9 It was not mentioned if 
the tests were also carried earlier. This is an 
important aspect because, testing so late is of 
no use because the COVID-19 patients can 
transmit disease if not detected at early 
stages of the disease.  
 
An another study from Wuhan Institute of 
Virology, Chinese Academy of Sciences found 
that on day 0 of testing, 81% (13 out of 16) of 
COVID-19 patients had detectable antibodies 
and by 5th day everybody had (either IgG or 
IgM or both).10⁠ But the study has not clarified 
the days when the patients were tested for 
immunoglobulins or the duration of days from 
onset of symptoms to hospitalization. The 
study used another technique called enzyme-
linked immunosorbent assay (ELISA) to detect 
the antibodies which have better limits of 
detection, hence sensitivity, compared to 
lateral flow assays in rapid diagnostic kits.11  
Research has shown that the increase in 
detectable immunoglobulins for SARS-CoV-2 
takes place only after more than 1 week of 
symptom onset.12⁠ Unlike immunoglobulins, 
the viral load is highest in the early days of 
onset and can be detectable by nucleic-acid 
amplification-based detection methods.12 Due 
to paucity of data on the ability of the 
immunoglobulin-based rapid diagnostic kits to 
detect infectivity as soon as symptoms arise, 
it’s difficult to conclude if such kits have any 
benefits to prevent transmission. So, the PCR 
or nucleic acid amplification-based technique 
still remains a validated method to detect 
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